Mukka Proteins Ltd Hits All-Time Low Amidst Prolonged Downtrend

Recent Price Movement and Market Context

The stock has experienced a consecutive five-day decline, resulting in a cumulative loss of 5.93% during this period. Despite this, it marginally outperformed the Aquaculture sector, which fell by 3.08% on the same day. Mukka Proteins’ price remained unchanged on 21 Jan 2026, contrasting with a slight 0.02% dip in the Sensex. However, the stock trades below all key moving averages – 5-day, 20-day, 50-day, 100-day, and 200-day – signalling sustained bearish momentum.

Over longer durations, the stock’s performance has been notably weak. It has declined by 44.82% over the past year, while the Sensex gained 8.34% in the same period. The one-month and three-month returns stand at -12.99% and -15.61% respectively, both significantly underperforming the Sensex’s 3.26% and 2.68% gains. Year-to-date, Mukka Proteins has lost 12.66%, compared to a 3.59% decline in the Sensex. The stock has also failed to register any gains over three and five years, contrasting sharply with the Sensex’s 35.53% and 65.57% growth over these intervals.

Financial Metrics and Profitability Analysis

Mukka Proteins’ financial indicators reveal challenges in profitability and capital efficiency. The company’s average Return on Capital Employed (ROCE) stands at 9.16%, a figure considered low within the FMCG sector, indicating limited profitability generated per unit of capital invested. This metric has contributed to the company’s current Mojo Grade of Sell, an improvement from a previous Strong Sell rating assigned on 14 Nov 2025, reflecting a slight stabilisation in outlook despite ongoing concerns.

Debt servicing capacity remains constrained, with a high Debt to EBITDA ratio of 5.26 times. This elevated leverage ratio suggests significant pressure on earnings before interest, taxes, depreciation, and amortisation to cover debt obligations. Correspondingly, interest expenses have reached a quarterly peak of Rs.12.82 crores, further impacting net profitability.

Sales Growth and Profit Trends

Net sales have grown at a modest annual rate of 8.60% over the past five years, indicating limited expansion in revenue generation. Despite this, operating profit has shown a comparatively healthy annual growth rate of 50.86%, suggesting some operational leverage. However, this has not translated into sustained bottom-line improvements.

The company has reported negative results for seven consecutive quarters. Quarterly Profit Before Tax excluding other income (PBT LESS OI) declined sharply by 67.9% to Rs.3.28 crores compared to the previous four-quarter average. Similarly, Profit After Tax (PAT) fell by 45.9% to Rs.5.88 crores in the latest quarter. These declines highlight ongoing pressures on profitability despite some operational gains.

Institutional Investor Sentiment

Institutional participation has diminished, with a 1.5% reduction in holdings over the previous quarter. Currently, institutional investors collectively hold only 1.86% of the company’s shares. This reduced stake by entities with extensive analytical resources may reflect cautious sentiment regarding the company’s fundamentals and outlook.

Comparative Performance and Valuation

Mukka Proteins’ valuation metrics present a mixed picture. The company’s Enterprise Value to Capital Employed ratio stands at 1.2, indicating a relatively attractive valuation compared to peers’ historical averages. This discount is notable given the stock’s underperformance and financial challenges. The Mojo Score of 31.0 further underscores the cautious stance, consistent with the Sell grade.

Profitability has deteriorated over the past year, with profits falling by 34%, aligning with the significant stock price decline. The company’s long-term growth prospects remain subdued, as reflected in the absence of gains over three and five years, contrasting with broader market indices.

Summary of Key Financial Indicators

The company’s financial profile is characterised by a low ROCE of 9.16%, a high Debt to EBITDA ratio of 5.26 times, and a recent peak in interest expenses at Rs.12.82 crores per quarter. Net sales growth remains modest at 8.60% annually over five years, while operating profit growth is comparatively robust at 50.86% per annum. Despite these operational gains, the company has reported seven consecutive quarters of negative results, with significant declines in quarterly PBT and PAT.

Institutional investors have reduced their holdings, now representing just 1.86% of total shares, reflecting a cautious stance. The stock’s performance has lagged the Sensex and sector indices across all measured time frames, including one month, three months, one year, and longer horizons.

Valuation metrics suggest the stock trades at a discount relative to peers, with an Enterprise Value to Capital Employed ratio of 1.2. The Mojo Score of 31.0 and a Sell grade indicate ongoing concerns about the company’s financial health and market position.

Market and Sector Comparison

Within the FMCG sector, Mukka Proteins’ recent performance contrasts with broader market trends. While the Aquaculture sector declined by 3.08% on the day the stock hit its all-time low, Mukka Proteins outperformed the sector by 2.89% on the same day, despite the absolute price level reaching a historic low. This relative outperformance, however, does not offset the broader negative trend seen over weeks, months, and years.

The Sensex’s positive returns over the past year and longer periods highlight the stock’s underperformance in comparison to the overall market. The absence of gains over three and five years further emphasises the company’s challenges in delivering shareholder value.

Conclusion

Mukka Proteins Ltd’s stock reaching an all-time low of Rs.20.74 on 21 Jan 2026 marks a significant event in its market journey. The company faces multiple financial headwinds, including low capital efficiency, high leverage, and sustained declines in profitability. Institutional investor participation has waned, and the stock has underperformed both its sector and the broader market over various time frames. While valuation metrics indicate a discount relative to peers, the overall financial and market data reflect a company navigating a difficult phase within the FMCG sector.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →